Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07097493 · ClinicalTrials.gov registry record · Phase 4
Liposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty
A Phase 4 study, sponsored by Wake Forest University Health Sciences.
- Not yet
- Registry status
- Phase 4
- Development phase
- 90
- Enrollment target
NCT07097493 is a Phase 4 study that has not yet begun recruiting, run by Wake Forest University Health Sciences. The registered enrollment target is 90 participants.
The verdict
NCT07097493, a Phase 4 study, has not yet begun recruiting, sponsored by Wake Forest University Health Sciences.
- NOT YET RECRUITING
- Registry status
- Phase 4
- Development phase
- 90 participants
- Enrollment target
Study Summary
The purpose of this research study is to compare two different combinations of anesthetic medications to see which works the best in providing the longest lasting pain relief for total knee arthroplasty surgery. The drugs being used are liposomal bupivacaine compared to a combination of bupivacaine, clonidine, epinephrine, buprenorphine, and dexamethasone. Pain scores will be collected at different intervals during study participation.
Interventions
- DRUG Liposomal Bupivacaine
- DRUG Bupivacaine, Clonidine, Epinephrine, Buprenorphine and Dexamethasone (BPV-CEBD) Combination
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 90 participants |
| Start Date | 2026-08 |
| Est. Completion | 2026-12-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07097493
The ClinicalTrials.gov registry entry for NCT07097493 describes a study currently listed as not yet recruiting, categorized as Phase 4. The registered enrollment target is 90 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Wake Forest University Health Sciences, which has 1,140 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Liposomal Bupivacaine is the first listed.
NCT07097493 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07097493 about?
NCT07097493 is a clinical study titled "Liposomal Bupivacaine vs Perineural Adjuvants in Adductor Canalf and iPACK Blocks in Total Knee Arthroplasty". The purpose of this research study is to compare two different combinations of anesthetic medications to see which works the best in providing the longest lasting pain relief for total knee arthroplasty surgery. The drugs being used are liposomal bupivacaine compared to a combination of bupivacaine,...
What is the current status of trial NCT07097493?
This trial is currently not yet recruiting. It is a Phase 4 study. The enrollment target is 90 participants. The study started on 2026-08. Estimated completion is 2026-12-31.
What interventions are being tested in trial NCT07097493?
The interventions under investigation include: Liposomal Bupivacaine (DRUG), Bupivacaine, Clonidine, Epinephrine, Buprenorphine and Dexamethasone (BPV-CEBD) Combination (DRUG).
Who is sponsoring clinical trial NCT07097493?
This trial is sponsored by Wake Forest University Health Sciences, which has 1,140 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.